Drugs / YH32367
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05523947 | Aug 2022 → Mar 2028 expected | — | Yuhan Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-29 | Yuhan Corporation | Results 유한양행, 미국암학회(AACR)서 면역항암제 YH32367 임상 1상, 렉라자 LASER301 저항성 기전 결과 발표 yuhan.co.kr ↗
임상시험 결과, 모든 용량에서 용량 제한 독성(DLT) 반응이 없었으며, 최대 내약용량(MTD)에 도달하지 않았다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-29 | Yuhan Corporation | 유한양행, 미국암학회(AACR)서 면역항암제 YH32367 임상 1상, 렉라자 LASER301 저항성 기전 결과 발표 yuhan.co.kr ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH32367 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05523947 ↗ |